New Peer-Reviewed Study Demonstrates Ability of HemoScreen For Rapid Evaluation of Acute Leukemia Patients

Study Shows PixCell's HemoScreen™ May Be Used to Monitor Pathological Blood Samples, Improving Treatment Process for Hematological Patients

YOKNEAM ILIT, Israel, Oct. 13, 2020 /PRNewswire/ -- PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today the results of a new study published in the International Journal of Laboratory Hematology demonstrating that the company's HemoScreen point-of-care hematology analyzer is suitable for the evaluation and management of patients receiving chemotherapy treatment for hematological cancers.

Researchers from North Zealand Hospital, University of Copenhagen, Bispebjerg and Frederiksberg Hospital, Copenhagen, and the University of Southern Denmark compared HemoScreen with the Sysmex XN-9000 in 206 routine venous samples and 79 capillary bedside samples focusing on white blood cells (WBC), absolute neutrophil count (ANC), red blood cells (RBC), platelet count (PLT) and hemoglobin (HGB).

"Cancer patients receiving intensive chemotherapy often suffer from severe bone marrow suppression as a result of the treatment, requiring regular complete blood count (CBC) monitoring," said Dr. Avishay Bransky, CEO of PixCell Medical. "This study shows that the HemoScreen can provide quick and trustworthy results both for general and pathological samples. Having this device widely available can potentially eliminate extraneous hospital visits and significantly shorten necessary ones - a game changer for patients already burdened with illness and fatigue."

The data show that the HemoScreen provides rapid and clinically reliable test results for WBC, ANC, RBC, PLT and HGB using 40 μl venous or capillary blood, as well as at low concentrations for guiding transfusions and post-chemotherapy treatment. The research team also found that the HemoScreen was sufficiently sensitive to flag pathological samples and abnormal cells, including nucleated RBCs, immature granulocytes and blast cells, and greatly reduced turnaround time of test results.

HemoScreen, developed by PixCell Medical, is the only FDA-cleared hematology analyzer intended for use at the point-of-care (POC) that combines flow cytometry with digital imaging in a single platform. The portable, compact hematology analyzer performs the complete blood count (CBC) test within 6 minutes and uses disposable, single-use cartridges pre-saturated with all the necessary reagents for fast, lab-accurate and simple testing.

The study concluded that the HemoScreen is well-suited for smaller outpatient clinics and potentially for home use.

About PixCell Medical

PixCell Medical provides the first truly portable point-of-care blood diagnostic solution. Leveraging the company's patented Viscoelastic Focusing technology, along with AI-powered machine vision, PixCell's FDA-cleared and CE-cleared HemoScreen diagnostic platform shortens diagnostic results delivery from days to minutes. With just one drop of blood and within six minutes, PixCell delivers accurate readings of 20 standard blood count parameters, saving patients, clinicians and health systems significant time and costs.

For more information: www.pixcell-medical.com and follow PixCell on LinkedIn.

Media Contact:
Finn Partners for PixCell Medical
Lior Feigin
lior.feigin@finnpartners.com
@LiorFeigin

View original content:http://www.prnewswire.com/news-releases/new-peer-reviewed-study-demonstrates-ability-of-hemoscreen-for-rapid-evaluation-of-acute-leukemia-patients-301150886.html

SOURCE PixCell Medical

Back to news